Clinical trials: Small-Cell Lung Cancer, open to volunteers
Melanoma (Skin), Triple-Negative Breast Cancer
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to…
- Conditions
- Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Synovial Sarcoma
- Trial name
- NCT05492682
- Testing
- PeptiCRAd-1, Cyclophosphamide, Pembrolizumab
- Where
- 7 sites in Germany, Italy
- Volunteers
- 15 people
- Sponsor
- Valo Therapeutics Oy
Non Small Cell Lung Cancer
A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC
This is an open-label, fixed-sequence Phase I clinical study that evaluates the effect of multiple doses of aumolertinib on the pharmacokinetics of midazolam (CYP 3A4 probe substrate) in sensitive EGFR (Epidermal Growth Factor…
- Trial name
- NCT06926413
- Testing
- Aumolertinib；midazolam
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC)…
- Conditions
- Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
- Trial name
- NCT05363280
- Testing
- AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
- Where
- 7 sites in United States, Spain
- Volunteers
- 80 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Non Small Cell Lung Cancer
Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy
This is a prospective multicenter clinical study. This study aims to construct an auxiliary decision-making system for lung cancer immunotherapy combined with radiotherapy by fusing three modes of imagomics, clinicopathological…
- Trial name
- NCT05584267
- Testing
- radiotherapy, Chemotherapy + immunotherapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Hunan Province Tumor Hospital
Non-small Cell Lung Cancer, Brain Metastases
Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.
The goal of this interventional phase III clinical trial is to evaluate objective intracranial response rate (iORR) after a treatment with total cranial radiation therapy plus concomitant transdermal nitroglycerin (NTG) addition…
- Conditions
- Non-small Cell Lung Cancer, Brain Metastases, EGFR Gene Mutation
- Trial name
- NCT06238882
- Testing
- Nitroglycerin
- Where
- Mexico
- Volunteers
- 74 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Small Cell Lung Cancer
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain.
- Trial name
- SEZanne (NCT07155174)
- Testing
- ABBV-706, Atezolizumab, Etoposide
- Where
- 70 sites in United States, Belgium and 11 more
- Volunteers
- 180 people
- Sponsor
- AbbVie
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC
This single-site, biomarker-enriched, randomized Phase II study will evaluate osimertinib with or without cyclosporine A (CsA) in metastatic epidermal growth factor receptor (EGFR )-mutant non-small cell lung cancer (NSCLC) [exon…
- Trial name
- OCEAN (NCT07874490)
- Testing
- Osimertinib, Cyclosporine A (CsA), ctDNA Biopsy Panel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC)
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
The purpose of Part 1 of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokinetics of [68Ga]Ga-DFC413, and in Part 2 compare to [68Ga]Ga-NNS309 in patients with locally advanced or…
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer (BC), HR+/HER2- Lobular Breast Cancer (BC)
- Trial name
- NCT07630961
- Testing
- 68Ga-DFC413, 68Ga-NNS309
- Where
- 2 sites in Denmark, Japan
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Brain Metastases
Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis
This retrospective multicenter observational study aims to develop and externally validate a noninvasive deep learning model based on routine brain MRI to identify actionable driver alterations in patients with non-small cell…
- Trial name
- DL-DriverBM (NCT07373951)
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Ming Yang
Nonsmall Cell Lung Cancer Stage III
Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy
This is a multicenter, phase 2 non-randomized study to investigate the clinical feasibility and therapeutic efficacy of employing a MDT-based strategy in unresectable stage III ALK positive NSCLC following neoadjuvant alectinib…
- Trial name
- NCT07573696
- Testing
- After neoadjuvant alpelisib combined with chemotherapy, a multidisciplinary decision was made
- Volunteers
- 50 people
- Sponsor
- Wen-zhao ZHONG
NSCLC, Cancer
APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
APOLLO 11 main aim is to build a strong Italian long-lasting lung cancer network (in around 48 Italian centres) on real world data and translational research by creating a decentralized long-term national database (settle locally…
- Conditions
- NSCLC, Cancer, Lung Cancer, Adenocarcinoma of Lung
- Trial name
- NCT05550961
- Where
- Italy
- Volunteers
- 1,200 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NSCLC, Stage III, NSCLC, Stage IV
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Androgen Deprivation Therapy (ADT) triggers thymic revitalization and increases thymic output, enhancing baseline anti-tumor immunity and responses to immunotherapies.
- Trial name
- NCT06512207
- Testing
- Leuprorelin acetate + Sintilimab, Sintilimab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Jinzhou Medical University
Small Cell Lung Cancer Extensive Stage
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
The purpose of this study is to evaluate the application value of circulating tumor DNA(ctDNA) with efficacy evaluation and prognostic assessment in patients with unresectable SCLC, who were receiving radiotherapy and…
- Trial name
- NCT05066945
- Testing
- Observation
- Volunteers
- 40 people
- Sponsor
- Xiangya Hospital of Central South University
Lung Neoplasm Malignant
Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
Neoadjuvant immunotherapy combined with chemotherapy followed by surgery has become an important treatment strategy for resectable non-small cell lung cancer (NSCLC).
- Trial name
- NCT07890636
- Testing
- Adebrelimab, Adjuvant treatment
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Ruijin Hospital
Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
A Phase 2 Study of ABSK043 Combined With Osimertinib
This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer
- Trial name
- NCT07710612
- Testing
- ABSK043 in combination with Osimertinib
- Where
- 7 sites in China
- Volunteers
- 72 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Solid Tumors, ER+ Breast Cancer
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
- Conditions
- Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation
- Trial name
- NCT05490472
- Testing
- JAB-2485 (Aurora A inhibitor)
- Where
- 8 sites in United States, China
- Volunteers
- 102 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Malignant Pleural Effusions, NSCLC Stage IV
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.
- Trial name
- NCT05543330
- Testing
- M701 pleural infusion, Pleural drainage, Cisplatin pleural infusion
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
The goal of this clinical trial is to clarify the efficacy and safety of the high-dose alternate-day furmonertinib in NSCLC with leptomeningeal metastasis.
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis, Furmonertinib, EGFR Activating Mutation
- Trial name
- NCT07348965
- Testing
- Furmonertinib 320mg qod po, Furmonertinib 160mg qd po
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Oligometastatic Disease
125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer
Most patients with metastatic cancer eventually develop resistance to systemic therapy. A subset of patients experience oligoprogression, characterized by progression at a limited number of lesions while other disease sites…
- Trial name
- NCT07333651
- Testing
- Standard-of-Care Systemic Therapy, 125I Seed Implantation
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Li Min
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.